Free Light Chains & Monoclonal Gammopathies
Impact on Diagnostic Panels
Potential Savings
August 2008
Now in addition to being clinical appropriate and easier on the patient it can also make it economic sense. Although adding the free light chain assay adds costs (illustrated on this slide) removing the urine tests more then offsets these costs.
Potential Savings |
Jump to section:
- Introduction
- Diagnostic Tests
- Mayo Clinic 1960-2003
- Plasma Cell Proliferative Disorders
- Serum Protein Electrophoresis & Immunofixation Electrophoresis
- Serum Protein Electrophoresis & Immunofixation Electrophoresis
- Monoclonal Serum Proteins: Newly Diagnosed Multiple Myeloma (n=1027)
- Serum Protein Electrophoresis & Immunofixation Electrophoresis
- Urine Protein Electrophoresis & Immunofixation Electrophoresis
- Intact Immunoglobulin/Free Light Chain
- FLC Reference Range
- Diagnoses for 428 Patients Selected for Urine Monoclonal Protein
- Serum PEL & IFE Results: 428 Pts with Urine Monoclonal Protein
- Laboratory Results: 428 Patients with Monoclonal Urinary Protein
- Potential Savings
- Uses of Serum Free Light Chain Assay
- Diagnostic Test Panel for Suspected Monoclonal Gammopathies
- Questions?
External
link
PDF
document
Excel
document
Word
document